Holen Sie sich die Stockscreener-App
9.38
0.43%
0.04
Handel nachbörslich:
9.57
0.19
+2.03%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NEO?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$9.34
Offen:
$9.25
24-Stunden-Volumen:
4.89M
Relative Volume:
1.62
Marktkapitalisierung:
$1.21B
Einnahmen:
$628.25M
Nettoeinkommen (Verlust:
$-78.55M
KGV:
-15.13
EPS:
-0.62
Netto-Cashflow:
$-29.73M
1W Leistung:
+3.88%
1M Leistung:
+17.84%
6M Leistung:
-3.50%
1J Leistung:
-32.08%
1-Tages-Spanne:
$9.19
$9.575
1-Wochen-Bereich:
$8.68
$9.62
52-Wochen-Spanne:
$4.72
$19.11
Neogenomics Inc Stock (NEO) Company Profile
Firmenname
Neogenomics Inc
Sektor
Branche
Telefon
(239) 768-0600
Adresse
9490 NEOGENOMICS WAY, FORT MYERS, FL
Vergleichen Sie NEO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
9.38 | 1.18B | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
525.83 | 198.09B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
206.15 | 146.89B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
636.91 | 50.67B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
138.04 | 39.19B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
204.76 | 34.64B | 15.70B | 1.24B | 2.01B | 6.9036 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-07-29 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-05-15 | Eingeleitet | Guggenheim | Neutral |
| 2025-04-30 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-12-10 | Eingeleitet | Jefferies | Buy |
| 2024-05-01 | Fortgesetzt | Craig Hallum | Buy |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-08-21 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-02-24 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-02-01 | Hochstufung | Needham | Hold → Buy |
| 2022-08-26 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-22 | Herabstufung | Needham | Buy → Hold |
| 2022-06-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-03-29 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-29 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | Fortgesetzt | Stephens | Overweight |
| 2021-12-16 | Eingeleitet | Cowen | Outperform |
| 2021-11-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-02-25 | Fortgesetzt | Needham | Buy |
| 2021-02-25 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-12-11 | Fortgesetzt | BTIG Research | Buy |
| 2020-10-28 | Bestätigt | Needham | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-28 | Eingeleitet | Guggenheim | Buy |
| 2020-07-29 | Bestätigt | Needham | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Buy |
| 2020-04-21 | Fortgesetzt | Stephens | Overweight |
| 2020-03-02 | Fortgesetzt | Craig Hallum | Buy |
| 2020-02-28 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | Herabstufung | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | Bestätigt | Needham | Buy |
| 2019-05-01 | Bestätigt | Needham | Buy |
| 2019-03-29 | Bestätigt | Needham | Buy |
| 2019-01-03 | Eingeleitet | Needham | Buy |
| 2018-10-24 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | Eingeleitet | Leerink Partners | Outperform |
| 2018-05-02 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | Herabstufung | BTIG Research | Buy → Neutral |
| 2017-08-24 | Eingeleitet | Gabelli & Co | Buy |
| 2016-12-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Neogenomics Inc Aktie (NEO) Neueste Nachrichten
NeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 2025 - PharmiWeb.com
NeoGenomics unveils RaDaR ST at ESMO Congress 2025 - Traders Union
How to track smart money flows in NeoGenomics Inc.Bond Market & Capital Efficient Trading Techniques - newser.com
Measuring NeoGenomics Inc.’s beta against major indicesQuarterly Investment Review & Fast Moving Trade Plans - newser.com
Published on: 2025-10-13 23:26:51 - newser.com
Is NeoGenomics Inc. stock bottoming outQuarterly Portfolio Summary & Community Consensus Trade Alerts - newser.com
Will NeoGenomics Inc. stock gain from government policiesJuly 2025 Short Interest & Breakout Confirmation Trade Signals - newser.com
How hedge fund analytics apply to NeoGenomics Inc. stockJuly 2025 Final Week & Community Consensus Stock Picks - newser.com
How NeoGenomics Inc. stock compares to growth peersJuly 2025 Weekly Recap & Reliable Intraday Trade Plans - newser.com
Forecasting NeoGenomics Inc. price range with options dataJuly 2025 Catalysts & Safe Entry Momentum Stock Tips - newser.com
Is NeoGenomics Inc. (NG9) stock good for wealth creation2025 Geopolitical Influence & Growth Focused Entry Reports - newser.com
Volatility clustering patterns for NeoGenomics Inc.July 2025 Levels & Verified Swing Trading Watchlist - newser.com
Is NeoGenomics Inc. stock affected by interest rate hikesJuly 2025 Big Picture & AI Powered Buy/Sell Recommendations - newser.com
Published on: 2025-10-13 09:16:58 - newser.com
Regression analysis insights on NeoGenomics Inc. performanceExit Point & AI Driven Stock Movement Reports - newser.com
Earnings visualization tools for NeoGenomics Inc.2025 Support & Resistance & Weekly Chart Analysis and Trade Guides - newser.com
NeoGenomics rallies after court win in Natera patent dispute - MSN
NeoGenomics unveils Paletrra revolutionizing spatial proteomics - Traders Union
NeoGenomics' (NEO) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
What catalysts could drive NeoGenomics Inc. stock higher2025 Support & Resistance & Weekly Momentum Stock Picks - newser.com
Volume spikes in NeoGenomics Inc. stock – what they meanJobs Report & Verified Chart Pattern Signals - newser.com
Is NeoGenomics Inc. forming a bottoming baseEarnings Recap Report & Weekly Watchlist for Consistent Profits - newser.com
Is NeoGenomics Inc a good long term investmentMarket Liquidity Analysis & Options Trading Analysis Tools - earlytimes.in
United States Pathological Examination Market Growth & - openPR.com
NeoGenomics to Report Third Quarter 2025 Financial Results on October 28, 2025 - BioSpace
Press Release: NeoGenomics to Report Third Quarter 2025 Financial Results on October 28, 2025 - 富途牛牛
NeoGenomics Inc Stock Analysis and ForecastTrading Volume Surges & Outstanding Portfolio Tips - earlytimes.in
What valuation multiples suggest for NeoGenomics Inc. stock2025 Buyback Activity & Safe Capital Growth Stock Tips - newser.com
Piper Sandler Maintains NeoGenomics(NEO.US) With Buy Rating, Maintains Target Price $11 - 富途牛牛
NeoGenomics (NASDAQ:NEO) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
agilon health, Tandem Diabetes, NeoGenomics, Hims & Hers Health, and Oscar Health Stocks Trade Up, What You Need To Know - The Globe and Mail
NeoGenomics (NASDAQ:NEO) Trading 9.1% HigherHere's What Happened - MarketBeat
Strategies to average down on NeoGenomics Inc.2025 Earnings Surprises & Daily Entry Point Trade Alerts - newser.com
NeoGenomics (NASDAQ:NEO Shareholders Incur Further Losses as Stock Declines 7.5% This Week, Taking Five-year Losses to 79% - 富途牛牛
Opportunities in the Booming AI in Bioinformatics Market: A $26+ Billion Industry by 2029 Led by Thermo Fisher Scientific, Eurofins Scientific, Dassault Systemes, Illumina and NeoGenomics Laboratories - Yahoo
Finanzdaten der Neogenomics Inc-Aktie (NEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.95%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):